AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00929591 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT01735240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5069
Description: AZD5069 15 mg (3x5 mg capsules) single administration
Study NCT01735240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole 400 mg (2x200 mg tablets)
Study NCT01612754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noise reduction work place rules
Description: Information conferences for all theatre staff (100%)on the detrimal effects of high noise levels in the operating theatre. Issue of workplace rules on handouts and poster on theatre doors: Ban of all mobile phones from theatre. Only conversations about the ongoing case are allowed. No restocking etc. during an operation and no work in this operating room concerning other patients (e.g. later on the list). Turnig of of unnecessary suckers, warming devices etc. . No in and out during the procedure.~Technical: Sound Ears (TM, Sound Ear A.S. Copenhagen, Denmark) taped to all 4 Walls. Optical Telephones.
Study NCT01612754 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Presence of an examiner in the concerned theatre
Description: Research Clerk present in theatre, writes on note pad.
Study NCT03107611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus Cream, 1%
Study NCT03107611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Study NCT01752270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diane-35 pretreatment
Description: Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
Study NCT01752270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diane-35 pretreatment
Study NCT05586893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy and Electroacupuncture
Description: We used the following Bladder acupuncture points, Weizong (B40) in the middle of the popliteal fossa and Kunlun (B60) located in a depression between the lateral malleolus and the Achilles tendon. The subjects were instructed to report the De Qi perception (paresthesia or numbness) that was the advice to the researchers that the point was right punctured. After the De qi was reported, the needle remained in the acupuncture point for 20 minutes and was rotated three times more for the preservation of the effect. During this time, all subjects remained in the supine laying down position on the stretcher.
Study NCT03137420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Numeric Scale of Family Distress
Description: Questionnaires at 1, 3, 6 and 12 months
Study NCT01435603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Lifestyle Advice
Description: Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.
Study NCT01435603 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Lifestyle Advice
Description: Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.
Study NCT01435603 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advice Plus Lifestyle Intervention
Description: Standard clinical education offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits for lifestyle and cardiovascular risk factor management. Brief lifestyle advice delivered by a study research assistant at baseline, 6, 12, and 24 months. AND, participant offered free of charge access to an intensive lifestyle intervention offered in a community setting. Lifestyle interventions are delivered in community settings by lay instructors from community organizations who are centrally trained by the study team.
Study NCT03219138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acceleromyography
Description: Use of an uncalibrated acceleromyography
Study NCT01196507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol or with a maximum of 12.5 BD.
Study NCT01196507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
Study NCT01784445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Description: Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
Study NCT01784445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftazidime
Description: Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
Study NCT01870284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study NCT03765801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRTA9906 60 mg PR tablet
Description: GRTA9906 60 mg PR tablet
Study NCT03765801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRTA9906 60 mg IR capsule
Description: GRTA9906 60 mg IR capsule
Study NCT03107611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pimecrolimus Cream, 1%
Study NCT03221322 — intervention group
Intervention type: BEHAVIORAL
Intervention: Superlean
Description: Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.
Study NCT01186146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin monotherapy
Description: stopping clopidogrel at 1 year after DES
Study NCT01870284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT01186146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin,Clopidogrel
Description: continue aspirin and clopidogrel 1year after DES
Study NCT00686517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2b
Description: 1.5 ug/kg/week SC for 12 or 24 weeks
Study NCT01870284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered SC
Study NCT04321070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Phosphate
Description: A thin film of investigation product will be applied to the affected areas of the face once daily
Study NCT04321070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin Phosphate RLD
Description: A thin film of investigation product will be applied to the affected areas of the face once daily
Study NCT04321070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: A thin film of investigation product will be applied to the affected areas of the face once daily
Study NCT02004522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: PI3K Inhibitor
Study NCT02004522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Description: monoclonal antibody
Study NCT01787331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Given PO
Study NCT01787331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01787331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02566486 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Reciprocating system
Description: Different root canal instrumentation systems
Study NCT02566486 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Rotational system
Description: Different root canal instrumentation systems
Study NCT03831789 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cerebellar targeted rTMS
Description: 10 Hz cerebellar rTMS (250 pulses)
Study NCT02796651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (6 μg)
Description: Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
Study NCT02796651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol furmarate (20 μg)
Description: Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
Study NCT03831789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerebellar targeted rTMS
Description: 10 Hz cerebellar rTMS (250 pulses)
Study NCT03483025 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Skin Testing of Hair cleansing products
Description: 6 different commercially available shampoos
Study NCT01072422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation
Description: Use of trying to quit smoking instrument and quit smoking advice
Study NCT00911547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: 10 mg tablet taken once daily at bedtime for 16 weeks
Study NCT00911547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beclomethasone
Description: 200 ug inhaled, taken twice daily for 16 weeks
Study NCT00911547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo inhaler
Description: placebo inhaler taken twice daily for 16 weeks
Study NCT00911547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhaler
Description: placebo inhaler taken twice daily for 16 weeks
Study NCT00911547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo tablet
Description: placebo tablet taken once daily at bedtime for 16 weeks
Study NCT00686517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
Study NCT01550718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ESML-EX (Physical Activity Program)
Description: ESML-EX consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic.
Study NCT01550718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ESML-Social (Social Activity Program)
Description: ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session.
Study NCT04437017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine+NK-1 RA+5-HT3 RA
Description: On day 1-4, Olanzapine (5mg) is delivered orally after dinner.
Study NCT04437017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone+NK-1 RA+5-HT3 RA
Description: On first day, dexamethasone (12 mg) is given orally/intravenously within 30 minutes before cisplatin administrated, and on day 2-4, the given dose of dexamethasone is 8 mg.
Study NCT03635112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
Study NCT03635112 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TD-1473
Description: TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
Study NCT03635112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TD-1473
Description: TD-1473, at Dose A or Dose B depending upon arm, will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating. An additional 48 weeks either at Dose A or Dose B, depending on arm, may be administered if subjects finish the 12 week induction period.
Study NCT02853474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Palliative Care visit
Description: A PC visit is a visit done by a PC physician. Any kind of visits done by other professionals IS NOT a PC visit.~Five PC visits are scheduled in this arm.
Study NCT02853474 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: EORTC-QLQ-C30 questionnaire
Description: The Quality of Life is assessed with the QLQ-C30 questionnaire at baseline, 12 and 24 weeks after inclusion, as well as every 8 weeks thereafter.
Study NCT02853474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EORTC-QLQ-C30 questionnaire
Description: The Quality of Life is assessed with the QLQ-C30 questionnaire at baseline, 12 and 24 weeks after inclusion, as well as every 8 weeks thereafter.
Study NCT02853474 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: HADS score
Description: The depression is assessed with the HADS scale (Hospital Anxiety and Depression Scale) at baseline, and then 12 and 24 weeks after inclusion.
Study NCT02853474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HADS score
Description: The depression is assessed with the HADS scale (Hospital Anxiety and Depression Scale) at baseline, and then 12 and 24 weeks after inclusion.
Study NCT03136081 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Candidiasis infection occurence
Description: Candidiasis infection occurence
Study NCT05445622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: learning spinal mobilization with a force sensor
Description: Experimental group will use a force sensor (Active5) while learning spinal mobilization during the practice lab portion of the class. The force sensor will provide objective feedback to the students. Each student will be instructed on how to use the Active 5 device prior to utilization it in the classroom setting.
Study NCT05445622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: learning spinal mobilization with a force sensor
Description: Experimental group will use a force sensor (Active5) while learning spinal mobilization during the practice lab portion of the class. The force sensor will provide objective feedback to the students. Each student will be instructed on how to use the Active 5 device prior to utilization it in the classroom setting.
Study NCT04435262 — intervention group
Intervention type: OTHER
Intervention: Remote Monitoring
Description: Remote Monitoring Follow-up
Study NCT02857907 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: A blood sample is performed one year after kidney transplantation.
Study NCT04192448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Administration
Description: The clinical trial does not involve any treatment. Participant will be randomly assigned to receive alcohol (BAC = .08%) or water (BAC = .00%).
Study NCT04192448 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Alcohol Administration
Description: The clinical trial does not involve any treatment. Participant will be randomly assigned to receive alcohol (BAC = .08%) or water (BAC = .00%).
Study NCT04192448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mood Induction
Description: The clinical trial does not involve any treatment. Participants will be randomly assigned to receive an anger emotion induction or a control (neutral) mood induction.
Study NCT02796651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for formoterol fumarate
Description: Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
Study NCT02796651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol fumarate (12 μg)
Description: Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
Study NCT04192448 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mood Induction
Description: The clinical trial does not involve any treatment. Participants will be randomly assigned to receive an anger emotion induction or a control (neutral) mood induction.
Study NCT00911547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo tablet
Description: placebo tablet taken once daily at bedtime for 16 weeks
Study NCT02380352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Study NCT02380352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Study NCT02380352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
Study NCT05128435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood sample taken 3 to 5 months after the infection
Study NCT02155296 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restorative Practices Intervention
Description: RPI has the 3 core components of an optimal comprehensive positive youth development intervention:~(1) sustained relationships with adults-RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in circles; (2) skills building-RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building-As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension.
Study NCT04552535 — intervention group
Intervention type: DRUG
Intervention: Second line (2L) afatinib
Description: Afatinib
Study NCT04552535 — intervention group
Intervention type: DRUG
Intervention: Second line chemotherapy
Description: Chemotherapy
Study NCT02193269 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill
Description: you will receive 0.0 mg as a single daily dose for 4 days
Study NCT01803646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-101
Description: AM-101 gel for intratympanic injection
Study NCT01803646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel for intratympanic injection
Study NCT03244605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation Education
Description: General health education
Study NCT03244605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCM
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
Study NCT01020838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Florbetaben (BAY94-9172)
Description: Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
Study NCT02470936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.
Study NCT02175212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short term androgen deprivation
Description: * Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months
Study NCT02175212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long term androgen deprivation
Description: * Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)~* Bicalutamide 50 mg tablet every day for 2 months~* Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy
Study NCT02175212 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Short term androgen deprivation
Description: Minimum dose of 76 Gy (range 76-82 Gy)
Study NCT02175212 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Long term androgen deprivation
Description: Minimum dose of 76 Gy (range 76-82 Gy)
Study NCT03244605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell，taste weight and package
Study NCT01290237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin hydrocloride
Description: see description of study arms
Study NCT04118699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin oral tablet
Description: Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered investigational product (rifaximin) for 4 weeks
Study NCT04118699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Patients with chronic idiopathic intestinal pseudo-obstruction (CIIPO) or patients with chronic intestinal pseudo-obstruction (CIPO), secondary to systemic scleroderma, are administered placebo for 4 weeks